OSCRHealthcare · Healthcare PlansThe 11 Wall Street analysts covering Oscar Health, Inc. hold a median 12-month price target of $29 — -13.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 13 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Oscar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OSCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −13.0% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $20 → $27 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $35 → $39 |
| 7 Aug 2026 | UBS | Maintains | Neutral | $20 → $26 |
| 10 June 2026 | Barclays | Upgrade | Overweight | — |
| 10 June 2026 | Barclays | Upgrade | Overweight | $30 → $35 |
| 26 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | Baird | Maintains | Neutral | — |
| 7 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | UBS | Maintains | Neutral | — |
| 6 May 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 20 Apr 2026 | Jefferies | Upgrade | Hold | — |
| 9 Jan 2026 | UBS | Upgrade | Neutral | — |
| 5 Jan 2026 | Barclays | Upgrade | Equal-Weight | — |
| 11 Dec 2025 | Stephens & Co. | Initiates | Equal-Weight | — |
| 26 Nov 2025 | Piper Sandler | Upgrade | Overweight | — |
| 13 Nov 2025 | Wells Fargo | Maintains | Underweight | — |
| 10 Nov 2025 | Barclays | Maintains | Underweight | — |
| 7 Nov 2025 | UBS | Maintains | Sell | — |
| 14 Oct 2025 | Goldman Sachs | Initiates | Neutral | — |
| 7 Oct 2025 | Wells Fargo | Maintains | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSCR appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 34% of US stocks
Cheaper than 80% of US stocks
Cheaper than 24% of US stocks
Cheaper than 57% of US stocks
Higher than 90% of US stocks
Higher than 80% of US stocks
Higher than 60% of US stocks
Higher than 56% of US stocks
Higher than 89% of US stocks
Higher than 73% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Oscar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
On August 14, 2026, Oscar Health (OSCR) was added to the Zacks Rank #1 (Strong Buy) growth stocks list, along with MTCH and PBI, as reported by Zacks Investment Research.
Why it matters — A Zacks Rank #1 (Strong Buy) designation signals a favorable analyst ranking for OSCR that investors tracking the stock would note.
On August 12, 2026, Oscar Health (OSCR) was added to Zacks Investment Research's Rank #1 (Strong Buy) list of growth stocks, along with MTCH and PBI. The item notes that OSCR was included on this growth stocks list by Zacks.
Why it matters — An Oscar Health watcher would care because inclusion on Zacks' Strong Buy growth stocks list signals that the company is being recognized by a major research firm as a leading growth stock.
Oscar Health reported record profitability for the first half of 2026 and raised its full-year operating outlook. The company cited membership growth, disciplined pricing, favorable utilization trends, and lower administrative expense ratios as drivers.
Why it matters — A record first-half performance combined with an upgraded full-year outlook points to strengthening operational and financial momentum for Oscar Health.
Oscar Health reported half-year earnings showing record profitability for the first six months of 2026, with revenues rising 70% to $4.9 billion. The company's results reflect a changing customer base, as both Oscar Health and GoodRx highlight the role of technology in responding to evolving consumer needs.
Why it matters — Oscar watchers would note the company's record profitability and strong revenue growth as signs of financial momentum amid shifts in the health-insurance consumer landscape.
Seeking Alpha published the transcript of Oscar Health, Inc.'s (OSCR) Q2 2026 earnings call, covering the company's second-quarter 2026 results with management commentary.
Why it matters — OSCR watchers would care because the transcript provides the company's full discussion of its latest quarterly performance and outlook directly from management.
The 11 Wall Street analysts covering Oscar Health, Inc. have a median 12-month price target of $29, with estimates ranging from $19 to $39. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Oscar Health, Inc., 3 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Oscar Health, Inc. 83 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, Oscar Health, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies -13.0% from the last close, and Ticker Nerd's factor model ranks Oscar Health, Inc. 83 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Oscar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $39 over the next 12 months.
Oscar Health, Inc. returned +123.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Oscar Health, Inc. is a health insurance and healthcare technology company headquartered in New York, founded in 2012.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Best Growth Stocks to Buy for August 14th". On August 14, 2026, Oscar Health (OSCR) was added to the Zacks Rank #1 (Strong Buy) growth stocks list, along with MTCH and PBI, as reported by Zacks Investment Research.
Oscar Health, Inc. is a health insurance and healthcare technology company headquartered in New York, founded in 2012. The company focuses on delivering health coverage through a technology-driven, full-stack platform designed to simplify the healthcare experience for members. Oscar Health offers Individual & Family plans, small group coverage, and solutions tailored to Individual Coverage Health Reimbursement Arrangements (ICHRA), serving consumers, employers, and other organizations across various U.S. markets. Through its +Oscar technology services, the company provides infrastructure and tools to other payors and providers, enabling data-driven care management, member engagement, and plan administration. Oscar Health also operates the Lucie Health Marketplace, a platform that helps consumers compare and select health plans and related services, enhancing choice and transparency. Across its offerings, the company emphasizes intuitive digital engagement, virtual care access, and coordination with high-value clinical providers, positioning Oscar Health as a distinctive player in the managed health care and insurtech segments.
CEO Mr. Mark Thomas Bertolini · 2,305 employees · United States · https://www.hioscar.com